550 related articles for article (PubMed ID: 27373504)
21. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
23. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
24. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
25. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
26. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
28. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
29. Adoptive T-Cell Therapy for Solid Tumors.
Yeku O; Li X; Brentjens RJ
Am Soc Clin Oncol Educ Book; 2017; 37():193-204. PubMed ID: 28561728
[TBL] [Abstract][Full Text] [Related]
30. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
31. CAR-T in solid tumors: Blazing a new trail through the brambles.
Guo F; Cui J
Life Sci; 2020 Nov; 260():118300. PubMed ID: 32827541
[TBL] [Abstract][Full Text] [Related]
32. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
34. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
35. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
37. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
[TBL] [Abstract][Full Text] [Related]
38. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
39. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
40. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
